-
Mashup Score: 12FDA approves Xolair as first and only medicine for children and adults with one or more food allergies - 2 month(s) ago
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate…
Source: www.roche.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 125
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in…
Source: www.roche.comCategories: General Medicine News, Hem/OncsTweet-
INAVO120 phase 3 study is positive Fulvestrant + palbociclib +/- inavolisib (oral PI3Ki) in 1L metastatic HR+ breast cancer that progressed on or within 12 mo of adjuvant endocrine therapy in pts with a PI3Km met its primary endpt of PFS @OncoAlert #bcsm https://t.co/XysiNHa7Mj
-
-
Mashup Score: 125
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in…
Source: www.roche.comCategories: General Medicine News, Hem/OncsTweet-
INAVO120 phase 3 study is positive Fulvestrant + palbociclib +/- inavolisib (oral PI3Ki) in 1L metastatic HR+ breast cancer that progressed on or within 12 mo of adjuvant endocrine therapy in pts with a PI3Km met its primary endpt of PFS @OncoAlert #bcsm https://t.co/XysiNHa7Mj
-
-
Mashup Score: 125
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in…
Source: www.roche.comCategories: General Medicine News, Hem/OncsTweet-
INAVO120 phase 3 study is positive Fulvestrant + palbociclib +/- inavolisib (oral PI3Ki) in 1L metastatic HR+ breast cancer that progressed on or within 12 mo of adjuvant endocrine therapy in pts with a PI3Km met its primary endpt of PFS @OncoAlert #bcsm https://t.co/XysiNHa7Mj
-
-
Mashup Score: 1Roche | Digital health solutions enable healthcare professionals to make confident decisions - 5 month(s) ago
Digital health solutions can provide healthcare professionals with access to real-time data and support them in delivering better personalised care
Source: www.roche.comCategories: General Medicine News, Future of MedicineTweet-
Digital health solutions enable healthcare professionals to make confident decisions https://t.co/CWNekoyp8f @Roche #medicine #digitalhealth https://t.co/6xzJctgGBF
-
-
Mashup Score: 0Roche - Doing now what patients need next - 2 year(s) ago
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
Source: www.roche.comCategories: General Medicine News, Latest HeadlinesTweet-
FDA approves Xofluza for use in kids with flu https://t.co/SAZNSIeK1d
-
-
Mashup Score: 0Rocheās subcutaneous formulation of Tecentriq demonstrates positive Phase III results - 2 year(s) ago
IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung…
Source: www.roche.comCategories: Hem/Oncs, Latest HeadlinesTweet-
New study supports SQ formulation of Atezolizumab https://t.co/7ZIIflveEN
-
-
Mashup Score: 5Rocheās subcutaneous formulation of Tecentriq demonstrates positive Phase III results - 2 year(s) ago
IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung…
Source: www.roche.comCategories: Hem/Oncs, Latest HeadlinesTweet-
A new formulation of a SC PD-L1 inhibitor coming with atezolizumab āthis may reduce discomfort, and duration of treatment, compared to IV infusion. But questions about cost and compliance are next! ā¦@OncoAlertā© https://t.co/HYOOyypZWq
-
-
Mashup Score: 0Roche - Doing now what patients need next - 2 year(s) ago
WorldwideAbout RocheExploreStrategyBusinessSustainabilityLeadershipGovernanceHistorySolutionsExploreFocus areasPharma solutionsDiagnostics solutionsPipelineInnovationExploreTeam & structureInnovation processEthical standardsPartneringStoriesMediaInvestorsCareers About Roche About RocheStrategyBusinessSustainabilityLeadershipGovernanceHistory Solutions SolutionsFocus areasPharma…
Source: www.roche.comCategories: Latest Headlines, UrologyTweet-
IMscin001 tested Intravenous vs subcutaneous atezolizumab (n=371) in NSCLC. The primary endpoint of non-inferior PK (AUC) blood levels was met. Efficacy was a 2nd endpoint (small numbers will limit this). S/C therapy would be easier for hospitals and pts. https://t.co/wqNVjbYtx0 https://t.co/vAqmYlXYeb
-
-
Mashup Score: 1[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022 - 2 year(s) ago
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Division sales up 6%; continued strong sales of new medicines for severe diseases. Impact of…
Source: www.roche.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Roche reports phase 2 study with oral SERD did not meet PFS endpoint. More work to be done to understand where oral SERDS will best fit in ER+ MBC. https://t.co/syHI9rXcyl
-
OIT is daily consumption of increasing measured doses of a food while adhering to precautions, monitoring for reactions, and managing co-morbidities to ultimately reduce reaction severity and increase reaction thresholds. Or take a monthly shot. š¤ https://t.co/zoWnVejRyL